Beacon Pointe Advisors’s ImmunityBio IBRX Stock Holding History

Beacon Pointe Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$643K	Buy	73,497 +33,270	+83%	+$252K	﹤0.01%	1223
2026 Q1	$309K	Buy	40,227 +8,181	+26%	+$56K	﹤0.01%	1523
2025 Q4	$63.5K	Sell	32,046 -996	-3%	-$2.26K	﹤0.01%	1479
2025 Q3	$81.3K	Buy	33,042 +7,000	+27%	+$18K	﹤0.01%	1361
2025 Q2	$68.8K	Hold	26,042	–	–	﹤0.01%	1232
2025 Q1	$78.4K	Hold	26,042	–	–	﹤0.01%	1192
2024 Q4	$66.7K	Hold	26,042	–	–	﹤0.01%	1184
2024 Q3	$96.9K	Hold	26,042	–	–	﹤0.01%	1195
2024 Q2	$165K	Hold	26,042	–	–	﹤0.01%	1201
2024 Q1	$140K	Hold	26,042	–	–	﹤0.01%	1290
2023 Q4	$131K	Hold	26,042	–	–	﹤0.01%	1259
2023 Q3	$44K	Buy	+26,042	New	+$52.3K	﹤0.01%	1311

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Beacon Pointe Advisors's IBRX Position: Q2 2026 in Review

Beacon Pointe Advisors increased its ImmunityBio (IBRX) stake by 83% in Q2 2026, buying an estimated $252K and bringing the position to 73,497 shares worth $643K. The position accounts for ﹤0.01% of the portfolio, ranked #1223.

Beacon Pointe Advisors first reported a position in IBRX in Q3 2023 and has held it in 12 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Beacon Pointe Advisors held 73,497 shares of ImmunityBio worth $643K as of Q2 2026.
Beacon Pointe Advisors bought 33,270 ImmunityBio shares in Q2 2026, an estimated $252K.
ImmunityBio made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1223 holding.
Beacon Pointe Advisors first reported a position in ImmunityBio in Q3 2023 and has held it in 12 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.